India supplies a significant share of the medicines, vaccines, and diagnostics on the WHO List of Prequalified products, and Indian sites have been through more WHO Prequalification, or WHO PQ, inspections than almost any other manufacturing base in the world. That volume of experience should mean Indian manufacturers rarely fail. In practice, sites still fall down in remarkably consistent places, and the reasons are rarely about whether the product itself is safe or effective. They are about whether the site can prove, on paper and in practice, that it consistently controls what it claims to control.
This guide goes deep into what WHO Prequalification actually verifies, how the inspection and corrective action process works, and exactly where Indian manufacturing sites most often fail, whether that is at first assessment, at re-inspection, or in the years after a product is already prequalified and listed. If you are searching for WHO PQ consultants for Indian pharma, WHO prequalification GMP inspection preparation, how to pass WHO PQ site inspection, or WHO prequalification dossier support India, this is written for you.
What WHO Prequalification Actually Verifies
WHO Prequalification is a programme run by the World Health Organization to assess whether medicines, vaccines, and diagnostics meet global standards of quality, safety, and efficacy for procurement by UN agencies and other international funders, including UNICEF, the Global Fund, and Gavi. It is not a substitute for national regulatory approval. It sits alongside it, as a separate and genuinely tougher question: can this product be trusted for supply across dozens of countries and thousands of clinics with widely varying regulatory capacity, not just in the country where it was approved.
For Indian manufacturers, this distinction matters because a product can already hold a robust Central Drugs Standard Control Organisation approval and still fail WHO PQ, because the two processes are testing different things. National approval largely tests the product. WHO PQ tests the site’s ability to consistently reproduce that product, batch after batch, under real operating conditions, with documentation that a WHO assessor who has never visited the facility before can independently verify.
A full WHO PQ assessment for a finished pharmaceutical product typically includes:
- Review of the product dossier, including the Finished Pharmaceutical Product questionnaire and quality data on drug substance and drug product
- A Site Master File for every manufacturing site involved, prepared in the WHO and PIC/S format
- An on-site GMP inspection of the manufacturing and testing facilities, assessed against WHO GMP standards as set out in WHO Technical Report Series 986, Annex 2
- Verification that the site’s national regulatory authority is itself assessed as functional against the WHO Global Benchmarking Tool
That last point is one of the least discussed prerequisites of the entire programme. Even a technically flawless site can find its prequalification pathway affected by the maturity status of its national regulatory system, which is why India’s own NRA benchmarking exercise, confirming functional status across areas such as clinical trial oversight and market authorisation, was treated as a landmark development for the entire domestic manufacturing sector rather than a bureaucratic footnote.
Where Indian Sites Commonly Fail
- Dossier and Site Reality That Do Not Line Up
A recurring failure point, and one that mirrors what national regulators see as well, is a dossier that describes a process, a specification, or a control strategy that does not precisely match what the site actually does. Incomplete dossiers, missing quality summaries, and poor supporting data are cited repeatedly as reasons applications stall before an inspection is even scheduled. For sites with multiple product lines or contract manufacturing arrangements, this gap often comes from a dossier being drafted centrally by a regulatory team without a final, line-by-line reconciliation against current site SOPs and batch records.
- Data Integrity Gaps That Surface During Routine Studies
Raw data traceability failures during routine studies are a persistent theme in Indian site findings, and they tend to surface in the same way each time: a result exists in a summary report or a certificate of analysis, but the underlying raw data, the instrument printout, the bench sheet, the electronic audit trail, cannot be fully reconstructed on request. WHO assessors, like other stringent regulatory authorities, treat this as a fundamental quality system failure rather than a minor documentation gap, because it undermines confidence in every other result the site has reported.
- Analyst Training and Sponsor Oversight Deficiencies
Analyst training deficiencies under sponsor or quality unit oversight show up frequently enough in inspection findings to be treated as a distinct category rather than a subset of general training records. The pattern is usually the same: an analyst is qualified on paper, with a signed training record, but cannot demonstrate the underlying competence when questioned directly during the inspection, or the training record itself lacks evidence of practical assessment rather than a simple attendance sign-off.
- CAPA Programmes That Close on Paper But Not in Practice
WHO’s own corrective action process gives a manufacturer the opportunity to submit up to two corrective action plans following a site inspection, and depending on the nature and number of nonconformities, WHO may require objective evidence that those corrective actions have actually been implemented, not just documented. Sites that treat a CAPA as complete once a written response has been submitted, rather than once the underlying process has demonstrably changed, frequently find their corrective action plan rejected on the first attempt. In some cases, the number and criticality of nonconformities is significant enough that WHO requires a dedicated follow-up inspection specifically to verify implementation before the finding can be closed.
- Post-Prequalification Complacency
This is the failure point that gets the least attention in pre-assessment preparation, and it is arguably the most costly, because it happens after a product is already on the market. WHO conducts post-prequalification review, including for-cause inspections triggered by specific concerns or evidence of potential noncompliance, and these can result in products being delisted from the WHO Prequalified list entirely if critical nonconformities are found. A site that passed its original inspection cleanly can still find itself delisted years later if quality system discipline erodes over time, if change control is not consistently applied, or if a quality event is not escalated and investigated with the same rigour that characterised the original assessment. Delisting is a public action, published on the WHO website, and it affects every procurer relying on that listing, not just the specific finding that triggered it.
- Vendor and Raw Material Qualification Gaps
Vendor qualification is another area where paper compliance and practical compliance diverge. A vendor approval procedure that exists as a questionnaire and an occasional on-site assessment can look complete during a desk review, but WHO inspectors probe whether that qualification is genuinely risk-based and whether it extends meaningfully to active pharmaceutical ingredient suppliers and critical packaging material sources, not just finished-goods vendors. Weak or superficial vendor qualification is a common thread running through nonconformities that ultimately trace back to a raw material or component issue.
- Internal Audit Findings That Do Not Drive Real Change
Sites with mature internal audit programmes, running both intra-department and inter-department reviews on a scheduled cycle, are generally in a stronger position, but even well-structured internal audit systems fail Indian sites when deficiency reports are closed against a target timeline without the underlying root cause genuinely being addressed. A deficiency report issued within days of an internal audit finding, followed by a CAPA closed within a fixed window purely to meet an internal KPI, often reappears as a WHO inspection finding, because the same underlying process weakness was never actually resolved.
What Happens When a Site Fails
Failure at a WHO PQ inspection is rarely a single dramatic event. It is usually a documented sequence:
- Nonconformities are classified by severity following the on-site inspection
- The manufacturer is given the opportunity to submit corrective action plans, generally up to two attempts
- WHO reviews the evidence provided and decides whether the corrective action plan is acceptable
- Depending on the number and criticality of findings, WHO may require a follow-up inspection to verify that corrective actions have actually been implemented before closing the nonconformities
- If prequalification requirements are not met within agreed deadlines, the application can be cancelled, or an already-prequalified product can be delisted
For products that are prequalified with outstanding minor nonconformities, WHO may permit a formal “commitment to prequalification,” where the manufacturer commits in writing to address specific issues by an agreed deadline. This commitment is published in the WHO prequalification public report and verified during re-inspection, which means unresolved commitments are not a private matter between the manufacturer and WHO. They are visible to every regulator and procurer reviewing that product’s prequalification history.
Practical Steps for Indian Manufacturers Preparing for WHO PQ
- Reconcile the dossier against current site SOPs and batch records line by line before submission, rather than relying on a dossier drafted centrally without final site validation
- Run a dedicated raw data traceability exercise across routine studies, tracing results back to instrument output and bench records exactly as a WHO assessor would
- Move analyst training programmes beyond attendance sign-off to documented practical competence assessment, particularly for critical testing roles
- Treat every CAPA as incomplete until the underlying process change is verified in practice, not just documented in a written response
- Build post-prequalification vigilance into the quality system permanently, since delisting risk does not end once a product reaches the WHO Prequalified list
- Extend vendor qualification rigour genuinely to API and critical packaging suppliers, not only to finished-goods vendors
- Ensure internal audit CAPA closures are driven by verified root cause resolution rather than a fixed internal timeline
Where Quality and Vigilance Ltd Comes In
Preparing an Indian manufacturing site for WHO Prequalification, or sustaining compliance after a product is already listed, is exactly the kind of regulatory groundwork Quality and Vigilance Ltd supports clients through, alongside its core pharmacovigilance and regulatory affairs remit covering EMA, FDA, and MHRA requirements. The gap between a dossier that reads well and a site that can independently prove every claim in it under a WHO assessor’s questioning is where most Indian sites actually lose ground, not in the underlying science. For manufacturers preparing a first WHO PQ submission, remediating findings from a previous inspection, or protecting an already-listed product from post-prequalification risk, the support that genuinely changes the outcome looks like this:
- Reconciling dossiers against site reality before submission, not after a query is raised
- Building raw data traceability audits that mirror exactly what a WHO assessor will request
- Structuring CAPA responses around verified implementation rather than paper closure
- Establishing ongoing post-prequalification vigilance so a listed product stays listed
Get in touch with Quality and Vigilance Ltd today to build a WHO Prequalification readiness plan that holds up at inspection and stays compliant long after your product is listed